BFC Planning’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$127K Buy
1,157
+18
+2% +$2.01K 0.01% 1140
2026
Q2
$125K Buy
1,139
+150
+15% +$15.5K 0.01% 1136
2026
Q1
$103K Buy
989
+267
+37% +$28.4K ﹤0.01% 1093
2025
Q4
$74.5K Buy
722
+13
+2% +$1.26K ﹤0.01% 1205
2025
Q3
$64K Buy
709
+7
+1% +$613 ﹤0.01% 1091
2025
Q2
$61.7K Buy
702
+513
+271% +$44.5K ﹤0.01% 1041
2025
Q1
$17.2K Buy
189
+15
+9% +$1.35K ﹤0.01% 1522
2024
Q4
$15K Buy
174
+99
+132% +$8.96K ﹤0.01% 1574
2024
Q3
$7.13K Buy
+75
New +$7.12K ﹤0.01% 1877

Other funds holding PPH

BFC Planning's PPH Position: Q3 2026 in Review

BFC Planning increased its VanEck Pharmaceutical ETF (PPH) stake by 1.6% in Q3 2026, buying an estimated $2.01K and bringing the position to 1,157 shares worth $127K. The position accounts for 0.01% of the portfolio, ranked #1140.

BFC Planning first reported a position in PPH in Q3 2024 and has held it in 9 quarters since. 127 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • BFC Planning held 1,157 shares of VanEck Pharmaceutical ETF worth $127K as of Q3 2026.
  • BFC Planning bought 18 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $2.01K.
  • VanEck Pharmaceutical ETF made up 0.01% of BFC Planning's portfolio in Q3 2026, its #1140 holding.
  • BFC Planning first reported a position in VanEck Pharmaceutical ETF in Q3 2024 and has held it in 9 quarters since.
  • 127 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.